Basocellular Skin Cancer about Three Patients Treated with Vismodegib Review of your Action Mechanism

Melisa Huñis and Adrián P Huñis
Additional contact information
Adrián P Huñis: Oncología Integral Belgrano, (Integral Oncology Belgrano), Buenos Aires University, Maimonides University, Argentina

Cancer Therapy & Oncology International Journal, 2020, vol. 16, issue 4, 73-80

Abstract: Vismodegib (Erivedge®) is a hedgehog pathway inhibitor and is approved to treat locally advanced or metastatic basal cell carcinoma (BCC) not suitable for surgery or radiation therapy. Our main objectives were to study the intimate mechanism of action of this novel drug and to present three cases of our casuistry, the clinically evaluated objective response rate (ORR), as a contribution to the literature.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555945.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555945.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:16:y:2020:i:4:p:73-80

DOI: 10.19080/CTOIJ.2020.16.555945

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().